Pilot fMRI Studies of Aging-Related Effects of THC
Launched by YALE UNIVERSITY · Oct 15, 2024
Trial Information
Current as of November 13, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how THC, the active ingredient in cannabis, affects memory and learning in young to middle-aged adults. Researchers want to understand if using THC leads to immediate changes in how people remember things or learn new information. The study will involve two sessions for each participant, where some will receive THC and others will receive a placebo (a substance with no active effect) without knowing which one they have.
To participate, individuals need to be between 27 and 39 years old and should have used cannabis in the past two years, feeling "high" when they did. It's important that they can read and understand English and are willing to follow the study's guidelines. However, people with certain medical conditions, a history of serious side effects from cannabis, or those who are pregnant or breastfeeding will not be eligible. If you decide to join, you will undergo a screening process and participate in an MRI scan, which is a type of imaging test that allows researchers to see how your brain reacts to THC. This study is not yet recruiting participants, but it aims to shed light on how THC may impact memory and learning in adults.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • CNB use within past 2 years and felt "high" when used.
- • Able to read, speak, and understand English.
- • Able and willing to provide written informed consent, and willing to commit to the study protocol.
- Exclusion Criteria:
- • Current marijuana tolerance, desire to cut down, or cravings to use during periods of abstinence.
- • Positive screen for drug or alcohol (except CNB) on test day will result in rescheduling the appointment
- • History of adverse effects with CNB
- • CNB users who are abstaining
- • IQ \<80 on the Wechsler Abbreviated Scale of Intelligence
- • Inability to comprehend written instructions using the WRAT 4 reading achievement test
- • Pregnant, breastfeeding, and ineffective birth control methods
- • Unable or unsafe to have an MRI
- • Serious medical, neuro-ophthalmological, or neurological illness (e.g. cancer, seizure disorders, encephalopathy
- • History of head trauma with loss of consciousness \> 30 minutes or concussion lasting 30 days
- • Focal brain lesion seen on structural MRI
- • Any medical/neurological condition that could compromise neurocognitive performance (e.g. epilepsy, multiple sclerosis, fetal alcohol syndrome)
- • Anyone deemed unsafe to study personnel for any reason
- • Hearing loss such that subject cannot hear sounds at the levels (dB) or pitches (Hz) to be used in the study
- • Significant pain and/or reduced mobility in the arms
About Yale University
Yale University, a prestigious Ivy League institution located in New Haven, Connecticut, is renowned for its commitment to advancing medical research and clinical innovation. With a rich history of academic excellence and a robust infrastructure for scientific inquiry, Yale serves as a leading sponsor for clinical trials aimed at improving patient care and developing new therapeutic approaches. The university's multidisciplinary teams of researchers and clinicians collaborate to conduct rigorous and ethical studies, leveraging cutting-edge technologies and methodologies to address critical health challenges. Through its dedication to fostering an environment of inquiry and discovery, Yale University plays a pivotal role in translating research findings into clinical practice, ultimately enhancing health outcomes for diverse populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hartford, Connecticut, United States
Patients applied
Trial Officials
Godfrey Pearlson, M.D
Principal Investigator
Founding Director, Olin Neuropsychiatry Center; Yale University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported